Revium Rx 8-K, filed Jun 22, 2026
Revium Rx. (RVRC)
About this 8-K
Revium Rx filed this 8-K on June 22, 2026, reporting on events of June 16, 2026.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
| (Exact Name of Registrant as Specified in its Charter) |
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including
area code:
| n/a |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| N/A | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.
Resignation of Ms. Inna Martin from her positions as Director, Chief Operating Officer and President
On June 16, 2026, Ms. Inna Martin resigned from her position as a member of the Board of Directors of Revium Rx. (“we”, “us”, “our”, “Revium” or the “Company”) and as Chief Operating Officer and President thereof, effective immediately. Ms. Martin’s resignation was in light of certain differences in expectations between her and the Company. At the time of her resignation, Ms. Martin did not hold positions on any committees of the Board of Directors.
In connection with Ms. Martin’s departure, the Company’s subsidiary, Revium Rx Ltd. (“Revium Ltd.”) and Ms. Martin entered into a Termination Agreement and Waiver (the “Separation Agreement”), effective as of June 16, 2026, pursuant to which Ms. Martin’s employment and consultancy engagement with Revium Ltd. will terminate on September 10, 2026. Additionally, the exercise period for Ms. Martin’s vested stock options to purchase up to 2,440,000 shares of the Company’s common stock has been extended until September 30, 2028. Ms. Martin’s shares and options are subject to certain sale restrictions as contained in the Separation Agreement.
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| REVIUM Rx. | |||
| June 22, 2026 | By: | /s/ Amir Avraham | |
| Name: | Amir Avraham | ||
| Title: | Chief Executive Officer | ||
2